Entropion Treatment Market size is estimated to cross by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023-2035. Further, the market generated a notable revenue in the year 2022. The growth of the market can be attributed to the increasing number of elderly people, entropion is most commonly found in old people of the age 60 and above. According to the World Bank census, the total share of global population aged above 65 years in 2020 was 9.318%, up from 8.223% in 2015, and this share is expected to further increase in the upcoming years.
In addition to these, factors that are believed to fuel the market growth of entropion treatment include the rise in eye related in the world. Entropion is a condition in which the eyelid folds inwards, and can happen in either eyelid. It can lead to corneal ulcer, retinal infection, and even vision impairment due to corneal damage. According to the data by the World Health Organization (WHO), corneal opacities cause moderate to severe distance vision impairment or loss of vision in over 4.2 million people. Meanwhile, 2.2 billion people suffer from partial or complete blindness globally. The growing awareness regarding optical diseases, and penetration of healthcare services in remote areas worldwide are some of the major factors anticipated to drive the market growth.
Growth Drivers
Growing Population of Old-Adults - Entropion often only affects the lower eyelid and is more prevalent in older persons. In research of approximately 25,000 people over the age of 60, approximately 2% of patients had involutional entropion. The prevalence of entropion increased with age.
Rising Success Rate of Entropion Treatment -Transverse blepharotomy and marginal rotation is a popular treatment for entropion. Moreover, throughout ten days, the bolster and sutures are in place. For the treatment of upper and lower lid cicatricial entropion, this surgery has an 85% success rate.
Increased Use of Contact Lenses - A soft contact lens are used to correct the vision, that is compromised due to entropion affected eye. There are around 140 million contact lens wearers in the world. Out of which, nearly 45 million users are in the United States.
Rising Prevalence of Dry Eye Syndrome - Dry eye syndrome is a common symptom of entropion eye, it causes itchiness, dryness, and redness. A greater number of people are impacted by dry eyes and decreased tear production. Between 5 to 50 percent of people worldwide have a dry eye condition.
Rising Use of Eye Drops - Doctors prescribe the use of mild eye drops to avoid any irritation and redness in the eye. By 2020, at least 3 million people in the UK will use eye drops and ointments daily. Following this, about 2 million people began using eye drops and ointments less frequently than once per month.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~7% |
|
Regional Scope |
|
Treatment (Artificial Tears, Skin Tape, Anti-inflammatory Drugs, Surgery)
The global entropion treatment market is segmented and analyzed for demand and supply by treatment into artificial tears, skin tape, anti-inflammatory drugs, surgery, and others. Out of the five types of treatment of entropy, the surgery segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the rising success of the surgery for treating entropion. There are many types of surgery that can be opted for entropion treatment, including lateral tarsal strip, rotational or everting sutures, horizontal lid tightening, modified suture canthoplasty, lower lid retractor reinsertion, and others. After an average follow-up of 13 months, a small case series of 15 patients who received solely tarsal strip treatment demonstrated no recurrence of entropion.
End-user (Specialty Clinics, Hospital)
The global entropion treatment market is also segmented and analyzed for demand and supply by end-user into specialty clinics, hospital, and others. Amongst these three segments, the specialty clinics segment is expected to garner a significant share. Entropion patients frequently struggle to blink, which can cause irritability, infection, and fatigue of the eyes. An ophthalmologist should be contacted right away if a sudden and noticeable lid droop develops. Patients suffering from entropion requires various treatment, including non-invasive and surgical and it should be conducted in specialty clinics under expert guidance with the ophthalmic diagnostic equipment. In 2022, the United States have nearly 1000 eye surgery clinics. Moreover, there are around 1300 eye specialty clinics in India.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Treatment |
|
|
By End User |
|
North American Market Forecast
The North American entropion treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the rising cases of entropion in older adults and higher number of people suffering with dry eye issues. According to the American Academy of Ophthalmology, the prevalence of entropion increases with the age, it increased by around 1% for patients aged 60 to 69, nearly 2% for those aged 70 to 79, and around 8% for those above the age of 80. Moreover, in America, between 16 and 49 million people have dry eyes, which accounts for 15% of the population.
APAC Market Statistics
The Asia Pacific entropion treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market in the region is credited to large geriatric population in countries that increase the chances of entropion patients in the region, such as India and China. According to the data by the World Bank, the population above 65 years of age in India crossed 90,719,952 in 2020, while, it crossed 167,808,567 in China.
Bausch & Lomb Incorporated, announced the launch of hydration boost lubricant eye drops and micellar eyelid cleansing wipes, under the brand name BioTrue.
Novartis AG to acquire Vedere Bio, in order to expand its portfolio to ophthalmology and opto-genetic gene therapy technology for treating blindness.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?